NSE: ACUTAAS · 30 October 2026
- Acutaas Chemicals has risen 27.60% over 5 trading sessions; today's move is +0.68%.
- Acutaas Chemicals submitted its financial results for the quarter and half year ended September 30, 2026, reporting a Q2 revenue from operations of ₹4,369 million, representing a 42.7% year-on-year increase. Profit after tax for the quarter grew 71.4% year-on-year to ₹1,231 million with a PAT margin of 28.2%. Alongside the earnings, management revised its FY27 revenue growth guidance upward from 25% to around 30% and raised its EBITDA margin guidance to the 38-40% range.
- Trading volume was 1.36 times the 20-day average daily volume.
Acutaas Chemicals share price: 27.60% rise over 5 trading sessions
Acutaas Chemicals Ltd. (ACUTAAS) moved higher by 0.68% on Thursday, trading between an intraday low of ₹3,918.70 and a high of ₹4,020.00 before settling at ₹4,003.60.
The broader market and sector benchmarks showed diverging trends during the session, with the Nifty rising 0.51% while the Nifty Metal sector benchmark declined 0.54%. Acutaas Chemicals outperformed the sectoral trend, building on a robust trailing performance that includes a 27.60% return over the past 5 trading days and a 22.08% return over the past 20 trading days.
While no single confirmed catalyst was announced today, the price action coincides with strong recent operational results from its October 27, 2026 earnings filing, where the company reported a 42.70% year-on-year jump in Q2 FY27 revenue to ₹4,369 million and a 71.40% increase in PAT to ₹1,231 million. Management also raised its full-year FY27 revenue growth guidance to around 30% and EBITDA margins to 38-40%, supported by the recent inauguration of its South Korea manufacturing facility for high-purity semiconductor chemicals.
11.19 lakh shares traded by 30 October 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 8.20 lakh shares (1.36 times). The five-day average daily volume was 23.10 lakh shares. Separately, the NSE report for 29 October 2026 showed 6.58 lakh shares delivered, representing 22.42% of that day’s traded volume. The same report recorded 268,004 trades.
The stock's positive move aligns with heightened volume at 1.36 times the 20-day average and follows robust recent operational updates, including a 42.70% jump in Q2 FY27 revenue and an upward revision in full-year guidance.
Latest Company Developments
Acutaas Chemicals submitted its financial results for the quarter and half year ended September 30, 2026, reporting a Q2 revenue from operations of ₹4,369 million, representing a 42.7% year-on-year increase. Profit after tax for the quarter grew 71.4% year-on-year to ₹1,231 million with a PAT margin of 28.2%. Alongside the earnings, management revised its FY27 revenue growth guidance upward from 25% to around 30% and raised its EBITDA margin guidance to the 38-40% range.
Demonstrates accelerating financial performance and improved forward visibility driven by pharma intermediates and new semiconductor material capacities.
The company completed the acquisition of 100% equity share capital of Enchem Ami Organics Private Limited through the transfer of 10,000 equity shares from its subsidiary, Acutaas Chemicals Electrolytes Private Limited. Following this transaction, Enchem Ami Organics Private Limited became a direct wholly-owned subsidiary of Acutaas Chemicals Limited.
Simplifies corporate structure and consolidates ownership of specialized electrolyte and semiconductor-linked material operations.
Following shareholder approval at the 19th Annual General Meeting held on September 24, 2026, the company announced the re-appointment of Mr. Ram Mohan Lokhande as Whole Time Director for a five-year term effective February 8, 2027. Additionally, Mrs. Anita Bandyopadhyay was re-appointed as a Non-Executive Independent Director for her second consecutive five-year term starting February 8, 2027.
Ensures leadership continuity in technical operations and corporate governance for the next strategic growth phase.
a press release dated October 27, 2026, titled "Q2 & H1 FY27 Results".
Acutaas Chemicals Limited has informed the Exchange that Record date for the purpose of Dividend is 17-Sep-2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 14.44% on 30 September 2026. This compares with 14.17% on 30 June 2026, a change of +0.27 percentage points.
The filing reported 32 MF/UTI holders.
What to Watch Next
- Execution of the upgraded FY27 revenue growth guidance of around 30%
- Operational ramp-up and commercial output from the newly inaugurated South Korea manufacturing facility
- Delivery volume trends relative to the 20-day average volume of 1.36x
- Specialty chemicals segment recovery and performance in upcoming quarterly filings
Other Dated Coverage
- Acutaas Chemicals Share Price Jumps 8.64% Intraday, Closes 7.19% Higher | 29 October 2026 — 29 October 2026
- Acutaas Chemicals Share Price Today: Rises 10.79% in 2 Trading Sessions | 28 October 2026 — 28 October 2026
- Acutaas Chemicals Share Price Today: Rises 20.98% in 2 Trading Sessions | 27 October 2026 — 27 October 2026
More Acutaas Chemicals news and dated analysis →
Frequently Asked Questions
What is the latest Acutaas Chemicals company news?
Acutaas Chemicals submitted its financial results for the quarter and half year ended September 30, 2026, reporting a Q2 revenue from operations of ₹4,369 million, representing a 42.7% year-on-year increase. Profit after tax for the quarter grew 71.4% year-on-year to ₹1,231 million with a PAT margin of 28.2%. Alongside the earnings, management revised its FY27 revenue growth guidance upward from 25% to around 30% and raised its EBITDA margin guidance to the 38-40% range.
How strong was Acutaas Chemicals’s trading volume?
11.19 lakh shares traded, 1.36 times the 20-day average daily volume. The price and volume data are dated 30 October 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.